Potential Cardio-protective Role of Dapagliflozin in Post Myocardial Infarction Patients

Document Type : Original Article


1 medical pharmacology/ Faculty of medicine/Aswan university

2 medical pharmacology at faculty of medicine Assiut university

3 medical pharmacology/faculty of medicine/assiut university

4 cardiology department/Aswan hospital/Aswan university


Type II diabetes mellitus and ischemic heart disease (IHD) commonly coexist and can be dangerous. The sodium glucose cotransporter-II inhibitors (SGLT2i) are a new class of diabetes treatment that reduces IHD hospitalization and cardiovascular (CV) mortality. (SGLT2i) obviously results in a significant decrease in IHD risk; however, the mechanism of these effects is not clear. This study aimed to evaluate the possible treatment effect of dapagliflozin on diabetic patients with anterior (STEMI) treated by primary percutaneous coronary intervention (PCI).
A randomized control trial enrolled 60 type II diabetic patients with anterior (STEMI) treated by primary (PCI) from both genders and their ages above 18 years old. The patients were categorized to two groups, Group (A) included 30 patients did not take dapagliflozin but they took the ordinary anti-ischemic & anti heart failure drugs also anti-diabetic medications. Group (B) enrolled 30 patients received dapagliflozin and they treated by ordinary anti-ischemic, anti-heart failure drug therapy and anti-diabetic medications.
In group (B) treated by dapagliflozin there was statistically highly significant improvement in LV systolic function by GLS, LVEF and LVEDD and LVESD in comparison with group (A) (P value<0.0001).
Dapagliflozin played a substantial role in cardiac remodeling, including decrease the LVEDD, LVSD as well as improvement in left ventricular systolic function.


Main Subjects